英文_高盛_中国化妆品2024-2025年第一季度总结需求企稳与竞争态势；年初至今的重估已反映在中期周期中；买入巨子生物_上海家化_27页_2mb

🇨🇳 China Cosmetics Industry Analysis Summary (Goldman Sachs)

Market Update

• Demand & Competition:
  China's beauty sector showed stabilization in demand (flattish YoY growth) with reduced promotional intensity by global players, creating room for local brands to gain share. Onshore sales growth accelerated to 3.2% YoY in Q1/24, while DFS channels lagged (down 23%/11% YoY in Korea/Hainan).

• Valuation Cycle:
  The sector rerated to 30x PE (vs. global peers' averages), exiting the downcycle bottom, but limited upside expected as the industry reaches mid-cycle valuation levels.

Competitive Analysis

• Local brands improved market share (top 20 ranked brands gained 0.41% YoY during 2024), driven by pricing upcycles and premiumization. New players like Giant Biogene/Marubi led growth (30%+ YoY sales).
• MNCs softened promotional strategies, with L'Oréal/Estée Lauder/SK-II losing market share, while global players like La Roche-Posay/Lancôme held stable shares.

Key Trends:

• Online Sales: Tmall/Taobao/JD.com drove Q1/24 growth for local firms; Douyin remains critical for Gen Z engagement.
• 618 Festival: Early livestreaming (May 13) and stable discounts (~last year’s levels) expected.

Company Coverage & Ratings

1. Giant Biogene (Buy):

   • Comfy/Collgene brand GMV growth accelerated in Q1/25; target price HKD82.6 reflects MA approval progress and online scaling.
   • Catalysts: 618, medical aesthetics expansion.

2. Shanghai Jahwa (Buy):

   • Turnaround potential with cost efficiency gains; expected sales acceleration in Q2.

3. Bloomage (Sell):

   • Skincare remains an overhang; MA approvals lagging. Target price cut to RMB38.

4. Botanee (Neutral):

   • Mature KOA brand mix; teens% YoY growth expected; valuation at 20x discount to historical averages.

5. MGP/Marubi/Chicmax:

   • Emerging leaders with diversified category expansion (color cosmetics/personal care).

Valuation Drivers

• Idiosyncratic Rerating: Idiosyncratic drivers (e.g., medical aesthetics innovations, brand upcycles, Q1 performance) support the sector’s convergence with global norms.
• PE Analysis: Factor-based valuation (PEG) suggests 28x long-term fair value for mid-tier firms.

Key Risks

• Regulatory: Delays in MA approvals (NMPA review acceleration expected).
• Execution: Competitor imitation, trade wars intensification, offline channel penetration challenges.
• Macro: Economic deceleration affecting consumer spending.

附：数据图表参考（如618折扣变化、企业PE校准等）